The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation

Sumeyye Calp-Inal, Maria Ajaimy, Michal L. Melamed, Christina Savchik, Peter Masiakos, Adriana Colovai, Enver Akalin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We aimed to determine the prevalence and clinical significance of complement-binding donor-specific antibodies (DSA) detected up to 30 years after kidney transplantation. Group 1 patients included 284 consecutive DSA negative patients who underwent kidney transplantation after 1 May 2009. Group 2 included 405 patients transplanted before this date and followed at our center with functioning allografts. DSA were tested using Luminex Single Antigen and the C1q assay. In Group 1 patients, who were monitored prospectively, 31 (11%) developed de novo DSA during a median follow-up of 2.5 (1.9, 3.6) years. Of these, 11 (4%) had C1q+ and 20 (7%) had C1q negative DSA. In Group 2 patients, 77 (19%) displayed DSA. Among these, 33 (8%) had C1q+ and 44 (11%) had C1q negative DSA. The incidence of acute antibody-mediated rejection (AMR) was significantly higher in C1q+DSA patients in both Group 1 (45%) and Group 2 (15%) compared with C1q negative DSA (5% and 2%) and DSA negative patients (1% and 3%; P

Original languageEnglish (US)
JournalKidney International
DOIs
StateAccepted/In press - Nov 4 2015

Fingerprint

Kidney Transplantation
Anti-Idiotypic Antibodies
Tissue Donors
Antibodies
Allografts
Antigens
Incidence

ASJC Scopus subject areas

  • Nephrology

Cite this

The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation. / Calp-Inal, Sumeyye; Ajaimy, Maria; Melamed, Michal L.; Savchik, Christina; Masiakos, Peter; Colovai, Adriana; Akalin, Enver.

In: Kidney International, 04.11.2015.

Research output: Contribution to journalArticle

@article{43d955e67c354082ad2a37377f9a3ff1,
title = "The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation",
abstract = "We aimed to determine the prevalence and clinical significance of complement-binding donor-specific antibodies (DSA) detected up to 30 years after kidney transplantation. Group 1 patients included 284 consecutive DSA negative patients who underwent kidney transplantation after 1 May 2009. Group 2 included 405 patients transplanted before this date and followed at our center with functioning allografts. DSA were tested using Luminex Single Antigen and the C1q assay. In Group 1 patients, who were monitored prospectively, 31 (11{\%}) developed de novo DSA during a median follow-up of 2.5 (1.9, 3.6) years. Of these, 11 (4{\%}) had C1q+ and 20 (7{\%}) had C1q negative DSA. In Group 2 patients, 77 (19{\%}) displayed DSA. Among these, 33 (8{\%}) had C1q+ and 44 (11{\%}) had C1q negative DSA. The incidence of acute antibody-mediated rejection (AMR) was significantly higher in C1q+DSA patients in both Group 1 (45{\%}) and Group 2 (15{\%}) compared with C1q negative DSA (5{\%} and 2{\%}) and DSA negative patients (1{\%} and 3{\%}; P",
author = "Sumeyye Calp-Inal and Maria Ajaimy and Melamed, {Michal L.} and Christina Savchik and Peter Masiakos and Adriana Colovai and Enver Akalin",
year = "2015",
month = "11",
day = "4",
doi = "10.1038/ki.2015.275",
language = "English (US)",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation

AU - Calp-Inal, Sumeyye

AU - Ajaimy, Maria

AU - Melamed, Michal L.

AU - Savchik, Christina

AU - Masiakos, Peter

AU - Colovai, Adriana

AU - Akalin, Enver

PY - 2015/11/4

Y1 - 2015/11/4

N2 - We aimed to determine the prevalence and clinical significance of complement-binding donor-specific antibodies (DSA) detected up to 30 years after kidney transplantation. Group 1 patients included 284 consecutive DSA negative patients who underwent kidney transplantation after 1 May 2009. Group 2 included 405 patients transplanted before this date and followed at our center with functioning allografts. DSA were tested using Luminex Single Antigen and the C1q assay. In Group 1 patients, who were monitored prospectively, 31 (11%) developed de novo DSA during a median follow-up of 2.5 (1.9, 3.6) years. Of these, 11 (4%) had C1q+ and 20 (7%) had C1q negative DSA. In Group 2 patients, 77 (19%) displayed DSA. Among these, 33 (8%) had C1q+ and 44 (11%) had C1q negative DSA. The incidence of acute antibody-mediated rejection (AMR) was significantly higher in C1q+DSA patients in both Group 1 (45%) and Group 2 (15%) compared with C1q negative DSA (5% and 2%) and DSA negative patients (1% and 3%; P

AB - We aimed to determine the prevalence and clinical significance of complement-binding donor-specific antibodies (DSA) detected up to 30 years after kidney transplantation. Group 1 patients included 284 consecutive DSA negative patients who underwent kidney transplantation after 1 May 2009. Group 2 included 405 patients transplanted before this date and followed at our center with functioning allografts. DSA were tested using Luminex Single Antigen and the C1q assay. In Group 1 patients, who were monitored prospectively, 31 (11%) developed de novo DSA during a median follow-up of 2.5 (1.9, 3.6) years. Of these, 11 (4%) had C1q+ and 20 (7%) had C1q negative DSA. In Group 2 patients, 77 (19%) displayed DSA. Among these, 33 (8%) had C1q+ and 44 (11%) had C1q negative DSA. The incidence of acute antibody-mediated rejection (AMR) was significantly higher in C1q+DSA patients in both Group 1 (45%) and Group 2 (15%) compared with C1q negative DSA (5% and 2%) and DSA negative patients (1% and 3%; P

UR - http://www.scopus.com/inward/record.url?scp=84946124692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946124692&partnerID=8YFLogxK

U2 - 10.1038/ki.2015.275

DO - 10.1038/ki.2015.275

M3 - Article

C2 - 26535999

AN - SCOPUS:84946124692

JO - Kidney International

JF - Kidney International

SN - 0085-2538

ER -